GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.
Clinical Trials
1
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Recruiting
1
100.0%
No approval data available
- Glucotrack has received ethical approval from St. Vincent's Hospital Melbourne HREC for a year-long clinical study of its implantable continuous blood glucose monitor in patients with type 1 and type 2 diabetes. - The multi-center study will enroll up to 30 participants requiring intensive insulin therapy, with first implantations expected by July 2025 and potential extension to three years of monitoring. - Unlike traditional CGMs that measure glucose in interstitial fluid, Glucotrack's device directly measures blood glucose with no wearable component and is designed to function for up to three years.
- Glucotrack has successfully transitioned from preclinical to clinical stage in 2024, completing its first human clinical study of a fully implantable continuous blood glucose monitoring (CBGM) system with promising results. - The company's innovative CBGM technology features a 3-year sensor longevity, no on-body wearable component, and real-time measuring capabilities, potentially offering significant advantages for diabetes management. - With $16.3 million secured through multiple funding rounds and FDA Investigational Device Exemption approval expected in Q4 2025, Glucotrack is positioned to advance clinical trials and development milestones throughout 2025.
- Glucotrack successfully completed its first-in-human clinical study of a continuous blood glucose monitor implanted in the subclavian vein, with no serious adverse events reported. - The innovative device is designed for direct blood glucose measurement and offers potential three-year longevity without requiring external components, marking a significant advance in diabetes monitoring. - The four-day hospital study involving six diabetes patients demonstrated successful sensor placement and removal procedures, validating the safety profile of the implantable monitoring system.
